Summary
Estrogen (ER) and progesterone receptor (PgR) content of tumors were determined by both the dextrancoated charcoal (DCC) cytosol and immunocytochemical assays (ICA), and these hormone receptor results were compared to lymphocyte immunity against tumor antigen(s) for 52 breast carcinoma patients. Hormone receptor analysis by both methods demonstrated that 60% of the patients' tumors had ERs, while 44% were positive for PgRs. The ICA procedure was more sensitive than the cytosol technique for determining PgR content of the tumors. This increased sensitivity was not observed for ER by ICA. Patient age, tumor size, and nodal status were not related to the ER and PgR receptor status. A total of 21/52 (40%) of the patients had positive lymphocyte immunity against tumor antigen. This immunity was independent of patient age, tumor size, and nodal status. There was no significant relationship between lymphocytic immunity against tumor antigen and ER or PgR content of tumors, suggesting that patient lymphocyte immunity against tumor is independent of hormone receptor status. This is further evidence that lymphocyte immunity against tumor antigen status is an independent prognostic indicator that may be useful in the selection of a subset of node negative patients for adjuvant chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Fisher B, Redmond C, Fisher FR, Caplan R, other contributing NSABP investigators: Relative worth of estrogen and progsterone receptor and pathologic characteristics of differentiation as indicator of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6: 1076–1087, 1988
Kallioniemi O-P, Blanco G, Alavaikko M, Hietanen T, Mattila J, Lauslahti K, Lehtinen M, Koivula T: Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histograms in breast cancer. Cancer 62: 2183–2190, 1988
Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633, 1989
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987
Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathological findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8: 103–112, 1990
Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IB, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentration of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008–6014, 1989
Tanden AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302, 1990
Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i: 1398–1402, 1987
Watkins SM: Cancer prognosis predicted by preoperative lymphocyte responsein vitro. Br J Surg 63: 433–434, 1976
Cannon GB, Dean JH, Herberman RB, Keels M, Alford C: Lymphoproliferative response to autologous tumor extracts as prognostic indicators in patients with resected breast cancer. Int J Cancer 27: 131–139, 1981
Head JF, Wang F, Elliott RL, McCoy JL: Assessment of immunological competence and host reactivity against tumor antigens in breast cancer patients: Prognostic value and rationale and immunotherapy development. Ann N Y Acad Sci 690: 340–342, 1993
Oren ME, Herberman RB: Delayed cutaneous hypersensitivity reactions to membrane extracts of breast tumors. Clin Exp Immunol 9: 45–56, 1971
Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC: Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxy vitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51: 239–244, 1991
Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies: Histopathological, demographic, and biochemical correlations to endocrine response and survival. Cancer 66: 1663–1670, 1990
Pertschuk LP, Feldman JG, Eisenberg KB, Carter AC, Thelmo WL, Cruz WP, Thorpe SM, Christensen IJ, Rasmussen BB, Rose C, Greene GL: Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody: Relation to biochemical assay, disease-free survival, and clinical endocrine response. Cancer 62: 342–349, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elliott, R.L., Head, J.F. & McCoy, J.L. Comparison of estrogen and progesterone receptor status to lymphocyte immunity against tumor antigens in breast cancer patients. Breast Cancer Res Tr 30, 299–304 (1994). https://doi.org/10.1007/BF00665971
Issue Date:
DOI: https://doi.org/10.1007/BF00665971